for - fake meat - Bezos Center for Sustainable Protein

Review coordinated by Life Science Editors Foundation

Reviewed by: Dr. Angela Andersen, Life Science Editors Foundation

Potential Conflicts of Interest: None

Punch line: Activation of the yeast AMP-activated protein kinase (AMPK) negatively regulates MAGIC, inhibits the import of misfolded proteins into mitochondria & promotes mitochondrial biogenesis and fitness.

Why is this interesting? Maybe all those healthy things like caloric restriction, intermittent fasting, exercise etc that activate AMPK & extend lifespan do so by inhibiting MAGIC & preventing mitochondrial damage from misfolded proteins.

Background: Metabolic imbalance & loss of proteostasis are interconnected hallmarks of aging and age-related diseases. A mitochondria-mediated proteostasis mechanism called MAGIC (mitochondria as guardian in cytosol) concentrates cytosolic misfolded protein at the surface of mitochondria, where they are disaggregated by molecular chaperones, and then imported for degradation by mitochondrial proteases. Inhibition of this pathway prolongs protein aggregation in cytosol after proteotoxic stress, but excessive misfolded proteins in mitochondria can lead to mitochondrial damage.

Results: • Genetic screen for MAGIC regulators uncovered 145 genes. Loss of Snf1 (AMPK homolog) led to increased mitochondrial import even without proteotoxic stress. In contrast indirect, constitutive activation of Snf1 (e.g. low glucose) prevented the import of misfolded proteins in mitochondria.

• The data suggest that the reduced accumulation of misfolded proteins in mitochondria of Snf1-active cells is not due to enhanced intramitochondrial degradation nor to reduced levels of the misfolded protein, but rather due to blocked mitochondrial import.

• Deletion of HAP4 counteracted Snf1 activation and overexpression of Hap4 alone recapitulated Snf1 activation. The Hap2/3/4/5 complex activates the expression of nuclear encoded mitochondrial proteins. Their data suggest that high expression of mitochondrial preproteins due to an elevated Snf1-Hap4 axis compete with misfolded proteins for mitochondrial import.

• Proteotoxic stress led to a reduced growth rate & reduced mitochondrial fitness in high glucose medium but not under glucose limitation. The data suggest that low glucose, activation of Snf1 & prevention of misfolded protein import into mitochondria prevent the growth defect.

• Many neurodegenerative disease-associated aggregation-prone proteins (α-synuclein, FUSP525L, TDP-43, amyloid beta, C9ORF72-associated poly(GR) dipeptide) are detected in mitochondria of human patients or disease models and impair mitochondrial functions. Their data suggest that the import of α-synuclein & associated reduction in mitochondrial fitness can be counteracted by indirect AMPK/Snf1 activation (i.e. glucose limitation).

• Show data in yeast & human cells.

Discussion: This paper revealed an unexpected link between cellular metabolism and proteostasis through MAGIC/mitochondria.

• Snf1/AMPK is a key regulator of MAGIC & of misfolded protein import into mitochondria.

• Snf1/AMPK balances the mitochondrial metabolic and proteostatic functions in response to glucose availability and protects mitochondrial fitness under proteotoxic stress.

• The authors speculate that in high glucose, cells rely on glycolysis for ATP production and mitochondria ‘moonlighting’ in cellular proteostasis through MAGIC, but when glucose is limited and cells rely on oxidative phosphorylation for ATP generation, AMPK is activated and shuts down MAGIC, prioritizing the import of essential mitochondrial preproteins to ensure mitochondrial fitness and energy production.

• Acknowledge limitations: Snf1/Hap4 activation elevates the expression of hundreds of mitochondrial preproteins, not clear whether specific preproteins or cytosolic factors directly involved in inhibiting mitochondrial import, & that more details on mechanisms will be of interest.

• Caloric restriction & AMPK activation might contribute to lifespan extension by inhibiting MAGIC. In human, AMPK activity is elevated during health-benefitting activities such as exercise. Their data suggest that elevating AMPK activity may be beneficial in alleviating proteotoxicity associated with degenerative diseases - but hyperactivated AMPK has also been reported in several neurodegenerative diseases with proteostasis decline (Ang wonders- maybe AMPK is overwhelmed?).

THIS IS A GORGEOUS PAPER!

Future work - I can't wait to see the characterization of the ribosome biogenesis genes that they also pulled out as MAGIC regulators. Anticipating a translation, misfolded protein, mitochondria, aging axis :)

protein

examples of high protein (hard) wheats: - Khorasan - Durum - Hard White Wheat - Hard Red Wheat - Red Fife

Good for breads, pizza, and things where chew is more valuable.

examples of lower protein (soft) wheats: - Sonora - Spelt - Soft White - Soft Red - Einkorn

good for pastries, cakes, cookies, etc.

Review coordinated by Life Science Editors Foundation

Reviewed by: Dr. Angela Andersen

Potential Conflicts of Interest: None

Background: * mRNAs in polarized cells often have a distinct spatial localization patterns that enable localized protein production * In non-polarized cells, mRNAs encoding membrane and secretory proteins are predominantly translated on the endoplasmic reticulum (ER), some mRNAs are enriched on the mitochondrial surface, some mRNAs are bound to the RNA-binding protein (RBP) TIS11B at the surface of the rough ER in "TIS granules". * The translation of specific mRNAs in TIS granules allows assembly of protein complexes that cannot be established when the mRNAs are translated on the ER but outside of TIS granules (physiological relevance). * The canonical rough ER (CRER) is distinct from the TIS granule ER (TGER), and both are distinct from the cytosol.

Questions: * Do mRNAs that encode non-membrane proteins differentially localize to the ER or the cytosol? (in steady state) * Does the amount of protein synthesis differ depending on the subcytoplasmic location of an mRNA?

Summary: * A third of mRNAs that encode non-membrane proteins have a biased localization to TGER or CRER, indicating that the ER membrane is a general site of translation for both membrane and non-membrane proteins. * 52% of mRNAs that encode non-membrane proteins have a biased mRNA transcript localization pattern towards a single cytoplasmic compartment. the TGER, CRER or cytosol. * The localization at the TGER or CRER was largely controlled by a combinatorial code of AU-RBPs at the 3'UTR. TIS11B promotes mRNA localization to TGER and TIA1/L1 to CRER. * LARP4B bound to the 3'UTR promotes cytosolic localization. * The location of translation has an independent effect on protein levels independent of the RBPs/3'UTR: redirecting cytosolic mRNAs to the rough ER membrane increased their steady-state protein levels by two-fold, indicating that the ER environment promotes protein expression. * Compartment-enriched mRNAs differed in their mRNA production and degradation rates, as well as functional classes and levels of their encoded proteins. Therefore the cytoplasm is partitioned into different functional and regulatory compartments that are not enclosed by membranes. * low-abundance proteins are translated in the TGER region. mRNAs encoding zinc finger proteins and transcription factors were substantially enriched at the TGER. These gene classes are usually expressed at lower levels than others.. This localization may regulate protein complex assembly (membrane proteins that are translated in the TGER domain establish protein complexes that cannot be formed when the proteins are translated on the CRER). The TGER may ensure that low-abundance mRNAs are effectively translated into low-abundance proteins. * mRNAs that are the most stable and encode the most highly expressed proteins are enriched on the CRER and include helicases, cytoskeleton-bound proteins, and chromatin regulators, overturning the idea that most non-membrane protein-encoding mRNAs are translated in the cytosol. * mRNAs overrepresented in the cytosol had the highest production and degradation rates and were enriched in proteins involved in mRNA processing and translation factors, whose abundance levels require tight control.

Advance: Evidence for functional compartmentalization of non-membrane mRNA protein expression in the cytosol vs ER. In steady state, general localization of mRNAs to the ER promotes high protein levels.

Significance: Engineered 3'UTR sequences could potentially boost protein expression by localizing mRNAs to the ER in experimental settings, for vaccines etc.

Remaining questions/points: * How does the rough ER stimulate protein expression? * Does the mRNA localization affect complex formation and/or function of non-membrane proteins? * Does this occur in cells other than HEK293T? * Is this regulated?

Nuclear pore complex or NPC. There is a size exclusion. <60kDa to pass through unassisted.

As soon as this sequence is translated, the SRP binds it. Elongation is temporarily arrested. SRP-ribosome complex binds to the SRP receptor on the ER membrane. Translation now continues into the lumen of the ER. The SPR and its receptor are recycled.

What gives Amino acids their specific special properties?

How are peptide bonds formed? What is released?

What is a peptide bond?

What is the core sequence to a protein structure? Which letters are the Terminus and which is the alpha C?

What is in a protein structure

What are Amino Acids?

Thuluva, S., Paradkar, V., Turaga, K., Gunneri, S., Yerroju, V., Mogulla, R., Kyasani, M., Manoharan, S. K., Medigeshi, G., Singh, J., Shaman, H., Singh, C., & Rao, A. V. (2022). Selection of optimum formulation of RBD-based protein sub-unit covid19 vaccine (Corbevax) based on safety and immunogenicity in an open-label, randomized Phase-1 and 2 clinical studies (p. 2022.03.08.22271822). medRxiv. https://doi.org/10.1101/2022.03.08.22271822

Banerjee, P. (2022, February 13). Biological E seeks EUA for its Corbevax vaccine for 12-18 yrs age group. Mint. https://www.livemint.com/news/india/biological-e-seeks-eua-for-its-corbevax-vaccine-for-12-18-yrs-age-group-11644746753338.html

Li, Z., Tomlinson, A. C., Wong, A. H., Zhou, D., Desforges, M., Talbot, P. J., Benlekbir, S., Rubinstein, J. L., & Rini, J. M. (2019). The human coronavirus HCoV-229E S-protein structure and receptor binding. ELife, 8, e51230. https://doi.org/10.7554/eLife.51230

nature. (2021, November 9). Protein-based vaccines—With their inexpensive production protocols and logistical advantages—Could help to narrow the immunization gap between rich and poor countries https://t.co/pLunUiQl3n [Tweet]. @Nature. https://twitter.com/Nature/status/1458009972214747136

nature. (2021, April 16). Coronavirus variants: Where do they come from? How do we spot them? What do they mean for COVID vaccines, and future of the pandemic? Https://t.co/NRbORu2hoF [Tweet]. @Nature. https://twitter.com/Nature/status/1383093697374474240

Haseltine, W. A. (n.d.). Birth Of The Omicron Family: BA.1, BA.2, BA.3. Each As Different As Alpha Is From Delta. Forbes. Retrieved 30 March 2022, from https://www.forbes.com/sites/williamhaseltine/2022/01/26/birth-of-the-omicron-family-ba1-ba2-ba3-each-as-different-as-alpha-is-from-delta/

Corbevax: All About India’s First Protein Sub-Unit Covid Vaccine to be Given to 12-14 Age Group From Today. (2022, March 16). News18. https://www.news18.com/news/india/corbevax-all-about-indias-first-protein-sub-unit-covid-vaccine-to-be-given-to-12-14-age-group-from-today-4874345.html

Mahase, E. (2022). Covid-19: Sanofi and GSK to seek regulatory authorisation for protein based vaccine. BMJ, 376, o526. https://doi.org/10.1136/bmj.o526

Trevor Bedford. (2022, January 28). Omicron viruses can be divided into two major groups, referred to as PANGO lineages BA.1 and BA.2 or @nextstrain clades 21K and 21L. The vast majority of globally sequenced Omicron have been 21K (~630k) compared a small minority of 21L (~18k), but 21L is gaining ground. 1/15 [Tweet]. @trvrb. https://twitter.com/trvrb/status/1487105396879679488

Prof. Akiko Iwasaki. (2022, January 27). Vaccines that reduce infection & disease are needed to combat the pandemic. Here, @tianyangmao @BenIsraelow et al. Describe our new mucosal booster strategy, Prime and Spike, to induce such immunity via nasal delivery of unadjuvanted spike vaccine 🧵 (1/) https://biorxiv.org/content/10.1101/2022.01.24.477597v1 https://t.co/bcB5MFph9F [Tweet]. @VirusesImmunity. https://twitter.com/VirusesImmunity/status/1486510697332842498

Devlin, H., & correspondent, H. D. S. (2022, February 3). Novavax Covid vaccine approved for use in over-18s in UK. The Guardian. https://www.theguardian.com/society/2022/feb/03/novavax-covid-vaccine-approved-for-use-in-over-18s-in-uk

Moderna wins full approval for its Covid-19 vaccine, as Novavax seeks authorization for its version. (2022, January 31). STAT. https://www.statnews.com/2022/01/31/and-then-there-were-2-fda-gives-full-approval-to-modernas-covid-19-vaccine/

Marcus, A. A. (2022, January 13). COVID-19 spike protein paper earns an expression of concern. Retraction Watch. https://retractionwatch.com/2022/01/13/covid-19-spike-protein-paper-earns-an-expression-of-concern/

Eric Topol. (2021, November 27). View of key mutations of Omicron’s 50, with 30 in the spike protein, 15 in its receptor binding domain https://ft.com/content/42c5ff3d-e676-4076-9b9f-7243a00cba5e http://covariants.org @EllingUlrich @_b_meyer https://t.co/onMoNFVLFJ [Tweet]. @EricTopol. https://twitter.com/EricTopol/status/1464452102382448643

Novavax and Serum Institute of India Announce World Health Organization Grants Emergency Use Listing for NVX-CoV2373 COVID-19 Vaccine—Dec 17, 2021. (n.d.). Retrieved December 18, 2021, from https://ir.novavax.com/2021-12-17-Novavax-and-Serum-Institute-of-India-Announce-World-Health-Organization-Grants-Emergency-Use-Listing-for-NVX-CoV2373-COVID-19-Vaccine?sf156899079=1

What do we know about the new B.1.1.529 coronavirus variant and should we be worried? (n.d.). Retrieved 10 December 2021, from https://www.gavi.org/vaccineswork/what-we-know-about-new-b11529-coronavirus-variant-so-far

New Covid variant: How worried should we be? (2021, November 25). BBC News. https://www.bbc.com/news/health-59418127

Devlin, H., & Kollewe, J. (2021, November 26). BioNTech says it could tweak Covid vaccine in 100 days if needed. The Guardian. https://www.theguardian.com/society/2021/nov/26/biontech-says-it-could-tweak-covid-vaccine-in-100-days-if-needed

Evaluating Omicron and Other COVID Variants to Ensure Test Effectiveness. (n.d.). Abbott. Retrieved December 3, 2021, from https://www.abbott.com/corpnewsroom/diagnostics-testing/monitoring-covid-variants-to-ensure-test-effectiveness.html

Ag can bind with protein at Cys, His and Met residues.

Sun, W., Liu, Y., Amanat, F., González-Domínguez, I., McCroskery, S., Slamanig, S., Coughlan, L., Rosado, V., Lemus, N., Jangra, S., Rathnasinghe, R., Schotsaert, M., Martinez, J. L., Sano, K., Mena, I., Innis, B. L., Wirachwong, P., Thai, D. H., Oliveira, R. D. N., … Palese, P. (2021). A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses. Nature Communications, 12(1), 6197. https://doi.org/10.1038/s41467-021-26499-y

Greinacher, A., Thiele, T., Warkentin, T. E., Weisser, K., Kyrle, P. A., & Eichinger, S. (2021). Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. New England Journal of Medicine, 384(22), 2092–2101. https://doi.org/10.1056/NEJMoa2104840

Shrotri, M., Navaratnam, A. M. D., Nguyen, V., Byrne, T., Geismar, C., Fragaszy, E., Beale, S., Fong, W. L. E., Patel, P., Kovar, J., Hayward, A. C., & Aldridge, R. W. (2021). Spike-antibody waning after second dose of BNT162b2 or ChAdOx1. The Lancet, 398(10298), 385–387. https://doi.org/10.1016/S0140-6736(21)01642-1

Here’s Where That COVID-19 Vaccine Infertility Myth Came From—And Why It Is Not True. (n.d.). Retrieved June 18, 2021, from https://www.henryford.com/blog/2021/04/fertility-rumor-covid-vaccine

Saadat, S., Tehrani, Z. R., Logue, J., Newman, M., Frieman, M. B., Harris, A. D., & Sajadi, M. M. (2021). Single Dose Vaccination in Healthcare Workers Previously Infected with SARS-CoV-2. MedRxiv, 2021.01.30.21250843. https://doi.org/10.1101/2021.01.30.21250843

Trevor Bedford. (2021, January 14). After ~10 months of relative quiescence we’ve started to see some striking evolution of SARS-CoV-2 with a repeated evolutionary pattern in the SARS-CoV-2 variants of concern emerging from the UK, South Africa and Brazil. 1/19 [Tweet]. @trvrb. https://twitter.com/trvrb/status/1349774271095062528

DataBeers Brussels. (2020, October 26). ⏰ Our next #databeers #brussels is tomorrow night and we’ve got a few tickets left! Don’t miss out on some important and exciting talks from: 👉 @svscarpino 👉 Juami van Gils 👉 Joris Renkens 👉 Milena Čukić 🎟️ Last tickets here https://t.co/2upYACZ3yS https://t.co/jEzLGvoxQe [Tweet]. @DataBeersBru. https://twitter.com/DataBeersBru/status/1320743318234562561

Gordon, D. E., Hiatt, J., Bouhaddou, M., Rezelj, V. V., Ulferts, S., Braberg, H., Jureka, A. S., Obernier, K., Guo, J. Z., Batra, J., Kaake, R. M., Weckstein, A. R., Owens, T. W., Gupta, M., Pourmal, S., Titus, E. W., Cakir, M., Soucheray, M., McGregor, M., … Krogan, N. J. (2020). Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms. Science, 370(6521). https://doi.org/10.1126/science.abe9403

Andrew💙Croxford. (2020, December 3). NEW THREAD: possible development of anti-Syncytin responses after immunization with the SARS-CoV-2 spike protein-coding mRNA vaccines, based on a ‘homologous’ region shared between these proteins. [Tweet]. @andrew_croxford. https://twitter.com/andrew_croxford/status/1334593606196187136

Here’s what we know about the new variant of coronavirus | Sharon Peacock. (2020, December 22). The Guardian. http://www.theguardian.com/commentisfree/2020/dec/22/new-variant-coronavirus-genomic-sars-cov-2-pandemic

Hodcroft, E. B., Domman, D. B., Oguntuyo, K., Snyder, D. J., Diest, M. V., Densmore, K. H., Schwalm, K. C., Femling, J., Carroll, J. L., Scott, R. S., Whyte, M. M., Edwards, M. D., Hull, N. C., Kevil, C. G., Vanchiere, J. A., Lee, B., Dinwiddie, D. L., Cooper, V. S., & Kamil, J. P. (2021). Emergence in late 2020 of multiple lineages of SARS-CoV-2 Spike protein variants affecting amino acid position 677. MedRxiv, 2021.02.12.21251658. https://doi.org/10.1101/2021.02.12.21251658

by attaching acceptor and donor to different domains of a target protein, the interdomain dynamics can be monitored

The entirety of proteins that are expressed as a cell, tissue or an organism.

This is the process of a complementary mRNA copy of a single gene on the DNA that is created in the nucleus. The mRNA is smaller than the DNA so it can carry the genetic code into the ribosome and into the cytoplasm that enables the protein creation.

This is a single strand on an RNA molecule that leaves the the nucleus of a cell in order to relocate to the cytoplasm. This is where the mRNA can help create the protein for the cell in a process known as protein synthesis. The mRNA takes in information passed into it by DNA and decode it for the ribosomes to make more protein for the cell to live on.

Ferretti, A. P., Kula, T., Wang, Y., Nguyen, D. M., Weinheimer, A., Dunlap, G. S., Xu, Q., Nabilsi, N., Perullo, C. R., Cristofaro, A. W., Whitton, H. J., Virbasius, A., Olivier, K. J., Baiamonte, L. B., Alistar, A. T., Whitman, E. D., Bertino, S. A., Chattopadhyay, S., & MacBeath, G. (2020). COVID-19 Patients Form Memory CD8+ T Cells that Recognize a Small Set of Shared Immunodominant Epitopes in SARS-CoV-2. MedRxiv, 2020.07.24.20161653. https://doi.org/10.1101/2020.07.24.20161653

Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., Dinnon, K. H., Elbashir, S. M., Shaw, C. A., Woods, A., Fritch, E. J., Martinez, D. R., Bock, K. W., Minai, M., Nagata, B. M., … Graham, B. S. (2020). SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature, 1–8. https://doi.org/10.1038/s41586-020-2622-0

Walls, A. C., Fiala, B., Schäfer, A., Wrenn, S., Pham, M. N., Murphy, M., Tse, L. V., Shehata, L., O’Connor, M. A., Chen, C., Navarro, M. J., Miranda, M. C., Pettie, D., Ravichandran, R., Kraft, J. C., Ogohara, C., Palser, A., Chalk, S., Lee, E.-C., … King, N. P. (2020). Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2. BioRxiv, 2020.08.11.247395. https://doi.org/10.1101/2020.08.11.247395

July 22, J. H. M. 2020 A.-493 P. O. F., & DOI 10.12788/jhm.3497, 2020 |. (2020). Effect of Systemic Glucocorticoids on Mortality or Mechanical Ventilation in Patients With COVID-19. Journal of Hospital Medicine, 15(8). https://doi.org/10.12788/jhm.3497

Martino, C., Kellman, B. P., Sandoval, D. R., Clausen, T. M., Marotz, C. A., Song, S. J., Wandro, S., Zaramela, L. S., Benítez, R. A. S., Zhu, Q., Armingol, E., Vázquez-Baeza, Y., McDonald, D., Sorrentino, J. T., Taylor, B., Belda-Ferre, P., Liang, C., Zhang, Y., Schifanella, L., … Knight, R. (2020). Bacterial modification of the host glycosaminoglycan heparan sulfate modulates SARS-CoV-2 infectivity. BioRxiv, 2020.08.17.238444. https://doi.org/10.1101/2020.08.17.238444

Yonker, L. M., Neilan, A. M., Bartsch, Y., Patel, A. B., Regan, J., Arya, P., Gootkind, E., Park, G., Hardcastle, M., John, A. S., Appleman, L., Chiu, M. L., Fialkowski, A., Flor, D. D. la, Lima, R., Bordt, E. A., Yockey, L. J., D’Avino, P., Fischinger, S., … Fasano, A. (2020). Pediatric SARS-CoV-2: Clinical Presentation, Infectivity, and Immune Responses. The Journal of Pediatrics, 0(0). https://doi.org/10.1016/j.jpeds.2020.08.037

Science Facebook Live: Understanding SARS-CoV-2 structure informs vaccine design, clinical trials. (2020, March 20). https://www.youtube.com/watch?v=nOzEx3OpKe8

Glasgow, A., Glasgow, J., Limonta, D., Solomon, P., Lui, I., Zhang, Y., Nix, M. A., Rettko, N. J., Lim, S. A., Zha, S., Yamin, R., Kao, K., Rosenberg, O. S., Ravetch, J. V., Wiita, A. P., Leung, K. K., Zhou, X. X., Hobman, T. C., Kortemme, T., & Wells, J. A. (2020). Engineered ACE2 receptor traps potently neutralize SARS-CoV-2. BioRxiv, 2020.07.31.231746. https://doi.org/10.1101/2020.07.31.231746

Bangaru, S., Ozorowski, G., Turner, H. L., Antanasijevic, A., Huang, D., Wang, X., Torres, J. L., Diedrich, J. K., Tian, J.-H., Portnoff, A. D., Patel, N., Massare, M. J., Yates, J. R., Nemazee, D., Paulson, J. C., Glenn, G., Smith, G., & Ward, A. B. (2020). Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate. BioRxiv, 2020.08.06.234674. https://doi.org/10.1101/2020.08.06.234674

LucyinLockdown: Viruses, Pandemics and Lessons Learnt with Dr Jane Greatorex—YouTube. (2020, June 18). https://youtu.be/5U1go5hyen8

Marshall, M. (n.d.). Everything you need to know about Russia’s coronavirus vaccine claims. New Scientist. Retrieved August 18, 2020, from https://www.newscientist.com/article/2251722-everything-you-need-to-know-about-russias-coronavirus-vaccine-claims/

Ou, T., Mou, H., Zhang, L., Ojha, A., Choe, H., & Farzan, M. (2020). Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2. BioRxiv, 2020.07.22.216150. https://doi.org/10.1101/2020.07.22.216150

Hsieh, C.-L., Goldsmith, J. A., Schaub, J. M., DiVenere, A. M., Kuo, H.-C., Javanmardi, K., Le, K. C., Wrapp, D., Lee, A. G., Liu, Y., Chou, C.-W., Byrne, P. O., Hjorth, C. K., Johnson, N. V., Ludes-Meyers, J., Nguyen, A. W., Park, J., Wang, N., Amengor, D., … McLellan, J. S. (2020). Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science. https://doi.org/10.1126/science.abd0826

Havers, F. P., Reed, C., Lim, T., Montgomery, J. M., Klena, J. D., Hall, A. J., Fry, A. M., Cannon, D. L., Chiang, C.-F., Gibbons, A., Krapiunaya, I., Morales-Betoulle, M., Roguski, K., Rasheed, M. A. U., Freeman, B., Lester, S., Mills, L., Carroll, D. S., Owen, S. M., … Thornburg, N. J. (2020). Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2020.4130

Clausen, T. M., Sandoval, D. R., Spliid, C. B., Pihl, J., Painter, C. D., Thacker, B. E., Glass, C. A., Narayanan, A., Majowicz, S. A., Zhang, Y., Torres, J. L., Golden, G. J., Porell, R., Garretson, A. F., Laubach, L., Feldman, J., Yin, X., Pu, Y., Hauser, B., … Esko, J. D. (2020). SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2. BioRxiv, 2020.07.14.201616. https://doi.org/10.1101/2020.07.14.201616

Yurkovetskiy, L., Wang, X., Pascal, K. E., Tomkins-Tinch, C., Nyalile, T., Wang, Y., Baum, A., Diehl, W. E., Dauphin, A., Carbone, C., Veinotte, K., Egri, S. B., Schaffner, S. F., Lemieux, J. E., Munro, J., Rafique, A., Barve, A., Sabeti, P. C., Kyratsous, C. A., … Luban, J. (2020). Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant. BioRxiv, 2020.07.04.187757. https://doi.org/10.1101/2020.07.04.187757

How scientists know COVID-19 is way deadlier than the flu. (2020, July 2). Science. https://www.nationalgeographic.com/science/2020/07/coronavirus-deadlier-than-many-believed-infection-fatality-rate-cvd/

Corbett, K. S., Edwards, D., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., Dinnon, K. H., Elbashir, S. M., Shaw, C. A., Woods, A., Fritch, E. J., Martinez, D. R., Bock, K. W., Minai, M., Nagata, B. M., … Graham, B. S. (2020). SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness. BioRxiv, 2020.06.11.145920. https://doi.org/10.1101/2020.06.11.145920

Zhang, L., Jackson, C. B., Mou, H., Ojha, A., Rangarajan, E. S., Izard, T., Farzan, M., & Choe, H. (2020). The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity. BioRxiv, 2020.06.12.148726. https://doi.org/10.1101/2020.06.12.148726

Starr, T. N., Greaney, A. J., Hilton, S. K., Crawford, K. H., Navarro, M. J., Bowen, J. E., Tortorici, M. A., Walls, A. C., Veesler, D., & Bloom, J. D. (2020). Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding [Preprint]. Microbiology. https://doi.org/10.1101/2020.06.17.157982

Bloom Lab. (2020, June 18). "We've experimentally measured how all amino-acid mutations to the #SARSCoV2 spike RBD affect ACE2 binding and expression of folded protein in a deep mutational scanning study led by @tylernstarr & Allie Greaney:https://biorxiv.org/content/10.1101/2020.06.17.157982v1 Why is this important? (1/n)" Twitter. https://twitter.com/jbloom_lab/status/1273468539484213248

Zhang, S. (2020, April 8). The Best Hopes for a Coronavirus Drug. The Atlantic. https://www.theatlantic.com/science/archive/2020/04/what-coronavirus-drug-will-look-like/609661/

Callaway, E. (2020). The race for coronavirus vaccines: A graphical guide. Nature, 580(7805), 576–577. https://doi.org/10.1038/d41586-020-01221-y

Experiment was performed using purified delftibactin, not whole cell Delftia. While this helps eliminate variables, we must make sure isolation and purification has no effect on protein function.

Wang, C., Li, W., Drabek, D. et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun 11, 2251 (2020). https://doi.org/10.1038/s41467-020-16256-y

Pay attention. ER Stress, and the Integrated Stress Response as well as Unfolded Protein Response

The biochemical changes are impressive.

A visual exploration of Tau protein related post-translational modifications in Alzheimers disease (and other tauopathies). Created with Biovista Vizit.

https://www.biovista.com/vizit-research/#!bv_gid=ba502df811e83f68ff3db71d2f33fff3

fdf

BLAST finds regions of similarity between biological sequences. The program compares nucleotide or protein sequences to sequence databases and calculates the statistical significance.